Clinical trial
Indentifying Epigenetic Biomarkers From Peripheral Blood of Osteosarcoma Patients Based on hMe-Seal Technique
NCT03336554 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Indentifying Epigenetic Biomarkers From Peripheral Blood of Osteosarcoma Patients Based on hMe-Seal Technique
- Lead sponsor
- Peking University People's Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- September 1, 2017
- Completion date
- December 31, 2018
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
histologic response (tumor necrosis rate), objective response rate for neoadjuvant chemotherapy, orr, overall survival, os, progression-free survival, pfs